

Rab40c Regulates Focal Adhesions and PP6 Activity by Controlling ANKRD28 Ubiquitylation

Ke-Jun Han, Valeryia Mikalayeva, Scott Gerber, Arminja Kettenbach, Vytenis Skeberdis, and Rytis Prekeris
DOI: <https://doi.org/10.26508/lsa.202101346>

Corresponding author(s): Rytis Prekeris, University of Colorado Anschutz Medical Campus

Review Timeline:

Submission Date:	2021-12-21
Editorial Decision:	2022-01-14
Revision Received:	2022-04-05
Editorial Decision:	2022-04-22
Revision Received:	2022-04-26
Accepted:	2022-04-26

Scientific Editor: Eric Sawey, PhD

Transaction Report:

(Note: With the exception of the correction of typographical or spelling errors that could be a source of ambiguity, letters and reports are not edited. The original formatting of letters and referee reports may not be reflected in this compilation.)

January 14, 2022

Re: Life Science Alliance manuscript #LSA-2021-01346-T

Prof. Rytis Prekeris
UC Denver
Cell and Developmental Biology
12801 E. 17th Ave.
Bldg. RC1, Room L18-12402
Aurora, CO 80045

Dear Dr. Prekeris,

Thank you for submitting your manuscript entitled "Rab40c Regulates Focal Adhesions and PP6 by Controlling ANKRD28 Ubiquitylation and Degradation" to Life Science Alliance. The manuscript was assessed by expert reviewers, whose comments are appended to this letter. We invite you to submit a revised manuscript addressing the Reviewer comments.

To upload the revised version of your manuscript, please log in to your account: <https://lsa.msubmit.net/cgi-bin/main.plex>

You will be guided to complete the submission of your revised manuscript and to fill in all necessary information. Please get in touch in case you do not know or remember your login name.

While you are revising your manuscript, please also attend to the below editorial points to help expedite the publication of your manuscript. Please direct any editorial questions to the journal office.

The typical timeframe for revisions is three months. Please note that papers are generally considered through only one revision cycle, so strong support from the referees on the revised version is needed for acceptance.

When submitting the revision, please include a letter addressing the reviewers' comments point by point.

We hope that the comments below will prove constructive as your work progresses.

Thank you for this interesting contribution to Life Science Alliance. We are looking forward to receiving your revised manuscript.

Sincerely,

Eric Sawey, PhD
Executive Editor
Life Science Alliance
<http://www.lsjournal.org>

A. THESE ITEMS ARE REQUIRED FOR REVISIONS

-- A letter addressing the reviewers' comments point by point.

-- An editable version of the final text (.DOC or .DOCX) is needed for copyediting (no PDFs).

-- High-resolution figure, supplementary figure and video files uploaded as individual files: See our detailed guidelines for preparing your production-ready images, <https://www.life-science-alliance.org/authors>

-- Summary blurb (enter in submission system): A short text summarizing in a single sentence the study (max. 200 characters including spaces). This text is used in conjunction with the titles of papers, hence should be informative and complementary to the title and running title. It should describe the context and significance of the findings for a general readership; it should be written in the present tense and refer to the work in the third person. Author names should not be mentioned.

-- By submitting a revision, you attest that you are aware of our payment policies found here: <https://www.life-science-alliance.org/copyright-license-fee>

B. MANUSCRIPT ORGANIZATION AND FORMATTING:

Full guidelines are available on our Instructions for Authors page, <https://www.life-science-alliance.org/authors>

We encourage our authors to provide original source data, particularly uncropped/-processed electrophoretic blots and spreadsheets for the main figures of the manuscript. If you would like to add source data, we would welcome one PDF/Excel-file per figure for this information. These files will be linked online as supplementary "Source Data" files.

IMPORTANT: It is Life Science Alliance policy that if requested, original data images must be made available. Failure to provide original images upon request will result in unavoidable delays in publication. Please ensure that you have access to all original microscopy and blot data images before submitting your revision.

Reviewer #1 (Comments to the Authors (Required)):

In this study Han et al. show that the GTPase Rab40c interacts with the cullin5 complex to form an active E3 ubiquitin ligase. This complex leads to the ubiquitination and degradation of the PP6 complex subunit ANKRD28. Degradation of ANKRD28 affects the distribution of paxillin, which is part of focal adhesions that promote the migration of cells along the ECM. Together this illustrates that PP6 activity is required for proper focal adhesion distribution at the leading edge of lamellipodia on migrating cells. Migration is thus altered by the recruitment of the Rab40/CRL5 complex to focal adhesions. This is a very well executed and controlled set of experiments that support the conclusions. Importantly, this advances the field in a significant manner and will be of broad interest to the audience. That being said, there are some points that should be addressed prior to publication.

In Figure 4G-H the authors show that ANKRD28 is ubiquitinated in a Rab40c dependent manner. Interestingly, they also show that the Ub linkage is at K63. This is consistent with the lack of an effect by the proteasome inhibitor MG132 as well as the block in degradation by the H⁺-ATPase inhibitor Bafilomycin. Together this shows that ANKRD28 degradation occurs in the lysosome. K-63 Ub labeling has been shown in autophagy as well as ESCRT dependent MVB sorting. Can the authors address these pathways, and which is likely/known to occur in this instance? To verify that ANKRD28 is transported to lysosomes it would be beneficial to see that there is colocalization with lysosomal markers.

How is Rab40c activity/binding to the Cullin5 complex dependent on its GTP binding or GTPase activity?

Is the Rab40c associated with Cullin5 inserted into a membrane? Could it be that Golgi Rab40c is trafficked to the plasma membrane to target focal adhesions?

Reviewer #2 (Comments to the Authors (Required)):

In this manuscript Han and co-workers have studied the role of the Rab40c isoform of the Rab40 subfamily in regulation of focal adhesion dynamics. They made the interesting discovery that Rab40c assembles with Cullin 5 into an E3 ubiquitin ligase complex that selectively binds and ubiquitinates targets for lysosomal degradation, such as several components of the PP6 protein phosphatase complex that are involved in FA regulation. Following selective Rab40c knock outs FAs are bigger, more numerous and lose their polarity towards the lamellipodia. Loss of Rab40c leads to stabilization of targets such as ANKRD28 (but possibly also others within the Rab40 interactome that they identified), which can be rescued by expression of Rab40c but not by a Rab40c variant that cannot interact with its substrates. They have characterized the binding requirements for Rab40c to ANKRD28 and PP6R1, and the data suggest that they can bind independently to Rab40c. From this the hypothesis arises that Rab40c regulation of FAs acts via degradation of (parts of) the PP6 complex, which alters phosphorylation of various targets associated with FA dynamics. Indeed, loss of ANKRD28 in many respects has the opposite phenotype as Rab40c KO and can actually reverse the latter. This correlates with effects on phosphorylation status and stability of components of the Hippo signaling pathway and with changes in transcriptional regulation by the YAP/TAZ complex.

The paper is well written and presents a comprehensive body of work with interesting findings that further our understanding of how Rab40c acts on the formation of FAs and on stability and function of the PP6 phosphatase complex.

Major comments

Functional assays of FA dynamics are limited to image quantification of FA localization, number and morphology, but do not assess effects on actual adhesive and migratory phenotype. Experiments aimed at determining changes in migration and adhesive behavior dependent on the Rab40c - PP6 axis would further strengthen this paper.

Although a lot of data is presented that details the molecular composition of the Rab40c regulatory complex and the signaling hierarchy that it controls, the main weakness of this study is that it remains unclear exactly where all these regulatory events take place. Where does Rab40c label its targets for degradation? In the lamellipodia, on the FA, somewhere in the cytosol, or on the Golgi? Figure 5 panels A and B show ectopically expressed FLAG-tagged ANKRD28 and PP6R1 somewhere in

lamellipodia. Is this representative for endogenous ANKRD28 and PP6R1? Are they part of the same structure and do they colocalize with (endogenous) Rab40c in lamellipodia subdomains? Figure 1 shows GFP-Rab40C also somewhere in lamellipodia, but it is not clear if this overlaps with its targets and again it is unclear to what extent this is representative of endogenous Rab40c. Endogenous localization of the players involved (Rab40c, PP6 components) would be very helpful for a better appreciation of what goes on, and how this changes in the absence of key components of this pathway as identified in this study.

Minor comments

In the proteomic survey of the Rab40c interactome a number of proteins were pulled down from the MDA-MB-231 cell lysates. Confirmation of these interactions using CO-IPs was performed in 293 cells, which seems less relevant and odd, considering MDA-MB-231 can also be used.

What's the level of ANKRD28 depletion throughout their experiments ? Can this be quantified?

I can't help to think that a lot of last minute rearrangement of panels and figures has taken place before submission, without updating the manuscript text accordingly. Some (but possibly not all) examples are: Figure 1B not mentioned in text, but referred to as 1C, 1D should be 1C, 1E-F should be 1D-E, Figure 4H incorrect (panel in figure, but no mention in text), Figure 5H incorrect (mentioned in text but no panel in H in the figure), Supplemental Figure 4 incorrect (mentioned in text, not actually present), two supplemental figures labeled Figure S3 in the supplement, mention of supplemental figure 2A in the IP of endogenous Rab40c from 293 cells makes little sense. The authors are advised to carefully proof read their article before submission, it would have saved me a lot of searching through the documents for figure panels that were mislabeled or non-existing.

We are very grateful to all reviewers for very constructive comments and suggestions. We incorporated vast majority of them, and I do believe that these changes significantly improved the manuscript. For the point-by-point changes see below.

Reviewer #1:

In this study Han et al. show that the GTPase Rab40c interacts with the cullin5 complex to form an active E3 ubiquitin ligase. This complex leads to the ubiquitination and degradation of the PP6 complex subunit ANKRD28. Degradation of ANKRD28 affects the distribution of paxillin, which is part of focal adhesions that promote the migration of cells along the ECM. Together this illustrates that PP6 activity is required for proper focal adhesion distribution at the leading edge of lamellipodia on migrating cells. Migration is thus altered by the recruitment of the Rab40/CRL5 complex to focal adhesions. This is a very well executed and controlled set of experiments that support the conclusions. Importantly, this advances the field in a significant manner and will be of broad interest to the audience. That being said, there are some points that should be addressed prior to publication.

1) In Figure 4G-H the authors show that ANKRD28 is ubiquitinated in a Rab40c dependent manner. Interestingly, they also show that the Ub linkage is at K63. This is consistent with the lack of an effect by the proteasome inhibitor MG132 as well as the block in degradation by the H⁺-ATPase inhibitor Bafilomycin. Together this shows that ANKRD28 degradation occurs in the lysosome. K-63 Ub labeling has been shown in autophagy as well as ESCRT dependent MVB sorting. Can the authors address these pathways, and which is likely/known to occur in this instance? To verify that ANKRD28 is transported to lysosomes it would be beneficial to see that there is colocalization with lysosomal markers.

As suggested, to confirm that ANKRD28 can be degraded by lysosomes, we tested whether ANKRD28 is present in CD63-positive (lysosomal marker) organelles. Since proteins targeted for lysosomal degradation are usually hard to detect we treated cells with Bafilomycin (inhibitor of lysosomal degradation). Our new data shows (see Figure 6C) FLAG-ANKRD28 puncta can be observed in lumen of CD63-positive organelles, which would be consistent with our model. It is more difficult to answer whether ANKRD28 is targeted to lysosomes via autophagy or via ESCRT-dependent MVB sorting since many inhibitors and lysosomal markers label both pathways. Since ANKRD28 is cytosolic protein, I suspect that autophagy is involved, but further studies will be needed to determine that. We added this discussion to the manuscript.

2) How is Rab40c activity/binding to the Cullin5 complex dependent on its GTP binding or GTPase activity?

As suggested we completed new binding experiments and now show that GTP-Rab40c binding to ANKRD28 is enhanced by GTP. This new data is now included in Supplemental Figure 2D.

3) Is the Rab40c associated with Cullin5 inserted into a membrane? Could it be that Golgi Rab40c is trafficked to the plasma membrane to target focal adhesions?

Since all Rab40-subfamily proteins binds to Cullin5 in GTP independent fashion (this can be associated with GDP-Rab40c and GTP-Rab40c) it is likely that it can associate with membrane bound Rab40c. It is also quite possible that Golgi Rab40c is trafficked to FAs from Golgi. That is actually how Rab18 (closes paralogue of Rab40 subfamily) functions. However, there is no easy way to answer these questions. We tried to address that by co-staining with Cullin5, but majority of Cullin 5 is cytosolic (since it binds to many other proteins in addition to Rab40c). Our previous work (PMID: 33999101) have shown that mutation of Cullin5 bidnign site within Rab40 proteins does not have any effect on Rab40b or Rab40c localization. That all suggest that Rab40c cycling and Rab40c binding to Cullin5 are regulated differentially. We are very interested expoling this, but that is outside the scope of this mansucipt.

Reviewer #2:

In this manuscript Han and co-workers have studied the role of the Rab40c isoform of the Rab40 subfamily in regulation of focal adhesion dynamics. They made the interesting discovery that Rab40c assembles with Cullin 5 into an E3 ubiquitin ligase complex that selectively binds and ubiquitinates targets for lysosomal degradation, such as several components of the PP6 protein phosphatase complex that are involved in FA regulation. Following selective Rab40c knock outs FAs are bigger, more numerous and lose their polarity towards the lamellipodia. Loss of Rab40c leads to stabilization of targets such as ANKRD28 (but possibly also others within the Rab40 interactome that they identified), which can be rescued by expression of Rab40c but not by a Rab40c variant that cannot interact with its substrates. They have characterized the binding requirements for Rab40c to ANKRD28 and PP6R1, and the data suggest that they can bind independently to Rab40c. From this the hypothesis arises that Rab40c regulation of FAs acts via degradation of (parts of) the PP6 complex, which alters phosphorylation of various targets associated with FA dynamics. Indeed, loss of ANKRD28 in many respects has the opposite phenotype as Rab40c KO and can actually reverse the latter. This correlates with effects on phosphorylation status and stability of components of the Hippo signaling pathway and with changes in transcriptional regulation by the YAP/TAZ complex. The paper is well written and presents a comprehensive body of work with interesting findings that futher our understanding of how Rab40c acts on the formation of FAs and on stability and function of the PP6 phosphatase complex.

Major comments

1) Functional assays of FA dynamics are limited to image quantification of FA localization, number and morphology, but do not assess effects on actual adhesive and migratory phenotype. Experiments aimed at determining changes in migration and adhesive behavior dependent on the Rab40c - PP6 axis would further strengthen this paper.

As suggested, we added cell adhesion analysis (now shown in new Figure 2). New data is fully consistent with our model and shows that Rab40c-KO has enhanced substrate adhesion.

2) Although a lot of data is presented that details the molecular composition of the Rab40c regulatory complex and the signaling hierarchy that it controls, the main weakness of this study is that it remains unclear exactly where all these regulatory events take place. Where does Rab40c label its targets for degradation? In the lamellipodia, on the FA, somewhere in the cytosol, or on the Golgi?

Figure 5 panels A and B show ectopically expressed FLAG-tagged ANKRD28 and PP6R1 somewhere in lamellipodia. Is this representative for endogenous ANKRD28 and PP6R1? Are they part of the same structure and do they colocalize with (endogenous) Rab40c in lamellipodia subdomains? Figure 1 shows GFP-Rab40C also somewhere in lamellipodia, but it is not clear if this overlaps with its targets and again it is unclear to what extent this is representative of endogenous Rab40c. Endogenous localization of the players involved (Rab40c, PP6 components) would be very helpful for a better appreciation of what goes on, and how this changes in the absence of key components of this pathway as identified in this study.

We fully agree with the reviewer that those are very interesting questions that we want to explore in the future but is outside the scope of this manuscript. Part of the issue is the fact that there are no good antibodies for ANKRD28, PP6R1 and Rab40c that work for microscopy. Furthermore, Rab40a, Rab40b and Rab40c are very closely related and we could not generate (despite numerous tries) antibodies that specifically recognize Rab40c by microscopy. At this point the only way to investigate dynamics of endogenous Rab40c is to generate knock-in GFP tags. That, however, is significant undertaking and outside the scope of this study.

Minor comments

1) In the proteomic survey of the Rab40c interactome a number of proteins were pulled down from the MDA-MB-231 cell lysates. Confirmation of these interactions using CO-IPs was performed in 293 cells, which seems less relevant and odd, considering MDA-MB-231 can also be used.

Our apologies for a mix up but immunoprecipitation experiments in Figure 4B and C were actually done using MDA-MB-231 cells. Experiments in Figure 4D-E were indeed done using 293T cells. The main reason for this is that MDA-MB-231 are difficult to transiently transfect. Consequently, to map PP6 interaction with rab40c we have used 293T cells.

2) What's the level of ANKRD28 depletion throughout their experiments? Can this be quantified?

As suggested, we added quantification of the level of ANKRD28 depletion (see Figure S3C).

3) I can't help to think that a lot of last minute rearrangement of panels and figures has taken place before submission, without updating the manuscript text accordingly. Some (but possibly not all) examples are: Figure 1B not mentioned in text, but referred to as 1C, 1D should be 1C, 1E-F should be 1D-E, Figure 4H incorrect (panel in figure, but no mention in text), Figure 5H incorrect (mentioned in text but no panel in H in the figure), Supplemental Figure 4 incorrect (mentioned in text, not actually present), two supplemental figures labeled Figure S3 in the supplement, mention of supplemental figure 2A in the IP of endogenous Rab40c from 293 cells makes little sense. The authors are advised to carefully proof read their article before submission, it would have saved me a lot of searching through the documents for figure panels that were mislabeled or non-existing.

Our apologies for the mistakes. We have proof-read the manuscript very carefully to fix all the mislabelled figures.

April 22, 2022

RE: Life Science Alliance Manuscript #LSA-2021-01346-TR

Prof. Rytis Prekeris
University of Colorado Anschutz Medical Campus
Cell and Developmental Biology
12801 E. 17th Ave.
Bldg. RC1, Room L18-12402
Aurora, CO 80045

Dear Dr. Prekeris,

Thank you for submitting your revised manuscript entitled "Rab40c Regulates Protein Phosphatase 6 Activity by Controlling ANKRD28 Ubiquitylation". We would be happy to publish your paper in Life Science Alliance pending final revisions necessary to meet our formatting guidelines.

Along with points mentioned below, please tend to the following:

- please add the Keywords for your manuscript in our system
- please add the Twitter handle of your host institute/organization as well as your own or/and one of the authors in our system
- please make sure the author names in our system match the author names in the manuscript
- please add the Author Contributions and a Conflict of Interest statement to the main manuscript text
- please use the [10 author names, et al.] format in your references (i.e. limit the author names to the first 10)
- please add a callout for Figure S2 A-C, S5, and S6 to the main manuscript text
- Thank you for providing your source data. This will be published alongside the manuscript, but it should not be included as supplementary figures. Please label figures S5 & S6 as source data, and update your figure legend accordingly.
- also, source data seem to be not correctly labeled. For example: 2A blots in Fig S5 file do not correspond with figure 2A.
- all the figures are blurred and very low quality, please provide higher resolution images.

If you are planning a press release on your work, please inform us immediately to allow informing our production team and scheduling a release date.

LSA now encourages authors to provide a 30-60 second video where the study is briefly explained. We will use these videos on social media to promote the published paper and the presenting author (for examples, see <https://twitter.com/LSAJournal/timelines/1437405065917124608>). Corresponding or first-authors are welcome to submit the video. Please submit only one video per manuscript. The video can be emailed to contact@life-science-alliance.org

To upload the final version of your manuscript, please log in to your account: <https://lsa.msubmit.net/cgi-bin/main.plex>
You will be guided to complete the submission of your revised manuscript and to fill in all necessary information. Please get in touch in case you do not know or remember your login name.

To avoid unnecessary delays in the acceptance and publication of your paper, please read the following information carefully.

A. FINAL FILES:

These items are required for acceptance.

- An editable version of the final text (.DOC or .DOCX) is needed for copyediting (no PDFs).
- High-resolution figure, supplementary figure and video files uploaded as individual files: See our detailed guidelines for preparing your production-ready images, <https://www.life-science-alliance.org/authors>
- Summary blurb (enter in submission system): A short text summarizing in a single sentence the study (max. 200 characters including spaces). This text is used in conjunction with the titles of papers, hence should be informative and complementary to the title. It should describe the context and significance of the findings for a general readership; it should be written in the present tense and refer to the work in the third person. Author names should not be mentioned.

B. MANUSCRIPT ORGANIZATION AND FORMATTING:

Full guidelines are available on our Instructions for Authors page, <https://www.life-science-alliance.org/authors>

We encourage our authors to provide original source data, particularly uncropped/-processed electrophoretic blots and spreadsheets for the main figures of the manuscript. If you would like to add source data, we would welcome one PDF/Excel-file per figure for this information. These files will be linked online as supplementary "Source Data" files.

****Submission of a paper that does not conform to Life Science Alliance guidelines will delay the acceptance of your manuscript.****

****It is Life Science Alliance policy that if requested, original data images must be made available to the editors. Failure to provide original images upon request will result in unavoidable delays in publication. Please ensure that you have access to all original data images prior to final submission.****

****The license to publish form must be signed before your manuscript can be sent to production. A link to the electronic license to publish form will be sent to the corresponding author only. Please take a moment to check your funder requirements.****

****Reviews, decision letters, and point-by-point responses associated with peer-review at Life Science Alliance will be published online, alongside the manuscript. If you do want to opt out of having the reviewer reports and your point-by-point responses displayed, please let us know immediately.****

Thank you for your attention to these final processing requirements. Please revise and format the manuscript and upload materials within 7 days.

Thank you for this interesting contribution, we look forward to publishing your paper in Life Science Alliance.

Sincerely,

Eric Sawey, PhD
Executive Editor
Life Science Alliance
<http://www.lsjournal.org>

Reviewer #1 (Comments to the Authors (Required)):

This is a resubmitted paper and the authors have satisfactorily addressed my critiques. As such, I believe that this paper is ready for publication.

Reviewer #2 (Comments to the Authors (Required)):

In their revised submission, Han and colleagues have added new experiments to address some of the points that I have raised. The authors have adequately responded to my comments.

April 26, 2022

RE: Life Science Alliance Manuscript #LSA-2021-01346-TRR

Prof. Rytis Prekeris
University of Colorado Anschutz Medical Campus
Cell and Developmental Biology
12801 E. 17th Ave.
Bldg. RC1, Room L18-12402
Aurora, CO 80045

Dear Dr. Prekeris,

Thank you for submitting your Research Article entitled "Rab40c Regulates Focal Adhesions and PP6 Activity by Controlling ANKRD28 Ubiquitylation". It is a pleasure to let you know that your manuscript is now accepted for publication in Life Science Alliance. Congratulations on this interesting work.

The final published version of your manuscript will be deposited by us to PubMed Central upon online publication.

Your manuscript will now progress through copyediting and proofing. It is journal policy that authors provide original data upon request.

Reviews, decision letters, and point-by-point responses associated with peer-review at Life Science Alliance will be published online, alongside the manuscript. If you do want to opt out of having the reviewer reports and your point-by-point responses displayed, please let us know immediately.

*****IMPORTANT:** If you will be unreachable at any time, please provide us with the email address of an alternate author. Failure to respond to routine queries may lead to unavoidable delays in publication.***

Scheduling details will be available from our production department. You will receive proofs shortly before the publication date. Only essential corrections can be made at the proof stage so if there are any minor final changes you wish to make to the manuscript, please let the journal office know now.

DISTRIBUTION OF MATERIALS:

Authors are required to distribute freely any materials used in experiments published in Life Science Alliance. Authors are encouraged to deposit materials used in their studies to the appropriate repositories for distribution to researchers.

You can contact the journal office with any questions, contact@life-science-alliance.org

Again, congratulations on a very nice paper. I hope you found the review process to be constructive and are pleased with how the manuscript was handled editorially. We look forward to future exciting submissions from your lab.

Sincerely,

Eric Sawey, PhD
Executive Editor
Life Science Alliance
<http://www.lsajournal.org>